89 completed, 25 terminated, 5 active not recruiting, 5 withdrawn. 65 Phase 1, 55 Phase 2, 15 Not applicable, 4 Phase 3, 2 Early Phase 1.
Follow Splenic Marginal Zone Lymphoma: new trials by email Literature Review of Splenic Marginal Zone Lymphoma trials Research Report on Splenic Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-12-16 | 2026-09-29 |
| Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies Chronic Lymphocytic Leukemia (CLL), Splenic Marginal Zone Lymphoma | Not yet recruiting | IRCCS San Raffaele | 64 | 2026-11-01 | 2026-08-13 | |
| Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) Epcoritamab - Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Recruiting | Izidore Lossos, MD | 25 | 2025-10-13 | 2026-10-15 |
| Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients Rituximab, Zanubrutinib - Splenic Marginal Zone Lymphoma | Phase 3 | Active not recruiting | International Extranodal Lymphoma Study Group (IELSG) | 122 | 2024-05-21 | 2026-07-22 |
| Study of SGR-1505 in Mature B-Cell Neoplasms SGR-1505 - Mature B-Cell Neoplasm, Non Hodgkin Lymphoma | Phase 1 | Recruiting | Schrödinger, Inc. | 98 | 2023-04-10 | 2026-02-13 |
| Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. CAR.k.28, Fludarabine, Cyclophosphamide - Mantle Cell Lymphoma, Follicular Lymphoma | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 20 | 2020-11-12 | 2026-01-20 |
| MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas Ibrutinib, Rituximab - Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma | Phase 2 | Active not recruiting | International Extranodal Lymphoma Study Group (IELSG) | 175 | 2019-09-27 | 2026-04-08 |
| Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma Splenic Marginal Zone Lymphoma | Completed | International Extranodal Lymphoma Study Group (IELSG) | 373 | 2017-01-01 | 2021-06-07 | |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration - Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma | Not applicable | Completed | Mayo Clinic | 29 | 2016-01-19 | 2019-11-15 |
| Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma carmustine, cytarabine, melphalan - Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma | Not applicable | Withdrawn | Fred Hutchinson Cancer Center | 2015-02-01 | 2015-05-07 | |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
| A Phase I/II Study of Intratumoral Injection of SD-101 Ipilimumab, SD-101, Radiation therapy - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 / Phase 2 | Completed | Robert Lowsky | 9 | 2014-09-01 | 2019-11-27 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 72 | 2014-09-01 | 2015-08-20 |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma PI3K inhibitor BKM120, rituximab, Pharmacodynamics - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 | Completed | Kami Maddocks, MD | 18 | 2014-07-21 | 2022-06-30 |
| Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma BTK inhibitor PCI-32765, rituximab, bendamustine hydrochloride - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 | Active not recruiting | Kami Maddocks, MD | 48 | 2014-03-26 | 2026-07-22 |
| Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant busulfan, etoposide, cyclophosphamide - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Early Phase 1 | Completed | Case Comprehensive Cancer Center | 33 | 2014-03-01 | 2015-08-13 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
Showing 20 of 129. Sign in to see all of them.
Lymphoma, B-Cell, Marginal Zone (125) · Lymphoma, Follicular (119) · Leukemia, Lymphocytic, Chronic, B-Cell (108) · Lymphoma, Mantle-Cell (108) · Lymphoma, Non-Hodgkin (98) · Lymphoma, Large B-Cell, Diffuse (97) · Waldenstrom Macroglobulinemia (95) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (91) · Burkitt Lymphoma (90) · Lymphoma, Large-Cell, Immunoblastic (85) · Mycosis Fungoides (69) · Sezary Syndrome (69) · Hodgkin Disease (67) · Lymphoma, T-Cell, Cutaneous (66) · Lymphoma, Large-Cell, Anaplastic (61)
Hemic and Lymphatic Diseases (127) · Immune System Diseases (127) · Immunoproliferative Disorders (127) · Lymphatic Diseases (127) · Lymphoproliferative Disorders (127) · Neoplasms by Histologic Type (127) · Neoplasms (126) · Lymphoma, B-Cell (123) · Hematologic Diseases (121) · Lymphoma (121) · Leukemia (112) · Leukemia, Lymphoid (112) · Disease Attributes (109) · Pathologic Processes (109) · Pathological Conditions, Signs and Symptoms (109)
Rituximab (33) · fludarabine phosphate (22) · Peripheral Blood Stem Cell Transplantation (21) · Whole-Body Irradiation (18) · Mycophenolic Acid (17) · Cyclophosphamide (16) · Cyclosporine (14) · Flow Cytometry (10) · Etoposide (8) · Bortezomib (7) · Busulfan (7) · Lenalidomide (7) · Tacrolimus (7) · Bendamustine Hydrochloride (6) · Vorinostat (6)
National Cancer Institute (NCI) (48) · Fred Hutchinson Cancer Center (25) · Mayo Clinic (8) · Case Comprehensive Cancer Center (6) · City of Hope Medical Center (6) · Roswell Park Cancer Institute (5) · International Extranodal Lymphoma Study Group (IELSG) (3) · Wake Forest University Health Sciences (3) · Kami Maddocks, MD (2) · Robert Lowsky (2) · University of Chicago (2) · University of Washington (2) · Barbara Ann Karmanos Cancer Institute (1) · Biocad (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1)
United States (119) · Italy (11) · France (4) · Germany (4) · Canada (3) · Switzerland (3) · Spain (2) · Ukraine (2) · Austria (1) · Belgium (1) · Colombia (1) · India (1) · Moldova (1) · Norway (1) · Poland (1)
Ajay Gopal (7) · David Maloney (6) · Brenda Sandmaier (4) · Thomas Witzig (4) · Ann Woolfrey (2) · Brenda Cooper (2) · George Chen (2) · John Byrd (2) · Kami Maddocks, MD (2) · Patricia LoRusso (2) · Paul Martin (2) · Philip McCarthy (2) · Ramesh Ramanathan (2) · Ryotaro Nakamura (2) · Sonali Smith (2)
PMID 32499241, PMID 40550489, PMID 18698002, PMID 19900571, PMID 20837940, PMID 21508413, PMID 21725056, PMID 22308288, PMID 23065509, PMID 23233721, PMID 23256542, PMID 24241210, PMID 24530971, PMID 25355819, PMID 26213141, PMID 26764356, PMID 27118452, PMID 28314788, PMID 28817727, PMID 29292843, PMID 29572391, PMID 30454872, PMID 31388792, PMID 31481800, PMID 31617432, PMID 32628342, PMID 33420905, PMID 34515338, PMID 34780125, PMID 36282798, PMID 40720747
P30CA015704 (14), U01CA076576 (8), P30CA015083 (7), P01CA018029 (5), U01CA062487 (5), U01CA062491 (5), U01CA062502 (5), U01CA099168 (5), U01CA062505 (4), N01CM17003 (3), N01CM62202 (3), P01CA044991 (3), P01CA078902 (3), P30CA014599 (2), P30CA016058 (2)